Allergan plc (AGN)

NYSE - NYSE Real Time Price. Currency in USD
221.66-0.33 (-0.15%)
As of 1:27 PM EDT. Market open.
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close221.99
Bid221.70 x 200
Ask221.80 x 100
Day's Range221.33 - 224.91
52wk Range195.50 - 322.68
1y Target EstN/A
Market Cap87.77B
P/E Ratio (ttm)21.10
Avg Vol (3m)3,301,864
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Can Allergan (AGN) Keep the Earnings Streak Alive in Q3?
    Zacks2 hours ago

    Can Allergan (AGN) Keep the Earnings Streak Alive in Q3?

    Allergan plc (AGN) will be reporting third-quarter 2016 earnings on Nov 2, before market open. Last quarter, the company delivered a positive earnings surprise of 2.13%.

  • American City Business Journals3 hours ago

    Allergan to acquire Boston drug company for $200M

    Allergan has announced it will acquire Boston-based Motus Therapeutics for $200 million. Motus, a wholly-owned subsidiary of Rhythm Holding Co. which also owns Rhythm Pharmaceuticals, is focused on developing peptide therapeutics for gastrointestinal disease. Allergan (AGN) previously paid $47 million for the option to acquire Motus, funding that also went to support Phase 2b clinical trials.

  • American City Business Journals6 hours ago

    $690M done deal: Allergan completes Vitae acquisition

    Allergan successfully completed its tender offer for all the outstanding shares of Vitae Pharmaceuticals Inc., a clinical-stage biopharmaceutical company based in Fort Washington, Montgomery County. Under the terms of the $639 million deal, Allergan (AGN) paid Vitae stockholders $21 per share. “The completion of the Vitae acquisition will add highly differentiated development compounds and bolsters our innovative medical dermatology pipeline,” said David Nicholson, chief research and development officer at Allergan.